Silzone-coated St. Jude medical valve: a safe valve.
Careful follow up studies in patients receiving a Silzone-coated St. Jude Medical valve (67 aortic valves, 36 mitral valves, nine double valves) did not support the fear of a high risk of perivalvular leak and embolism rate. Freedom from perivalvular risk at 12 and 24 months follow up was 98.5+/-1.5% and 100% for the aortic and mitral valves, respectively. Freedom from any thromboembolic event was 96.6+/-2.4% at 12 and 24 months follow up in the aortic group, and 97+/-3% at 12 and 24 months in the mitral group. The risk of bleeding (92.2+/-3.8% at 12 and 24 months in the aortic group; 85.5+/-6.0% in the mitral group) illustrated the risk of mechanical valve implantation in an elderly population.
Houël
R
R
Service de Chirurgie Thoracique et Cardiovasculaire, CNRS UPRESA 7054, Association Claude Bernard, Hôpital Henri Mondor, Créteil, France.
Kirsch
M
M
Hillion
M L
ML
Loisance
D
D
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000601:surgery*; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011475:Prosthesis Failure; D012307:Risk Factors; D012834:Silver; D013923:Thromboembolism / Q000209:etiology*; D013997:Time Factors
D012834:Silver